Harmony Biosciences (HRMY)
(Delayed Data from NSDQ)
$29.40 USD
+0.53 (1.84%)
Updated May 31, 2024 04:00 PM ET
After-Market: $29.44 +0.04 (0.14%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
HRMY 29.40 +0.53(1.84%)
Will HRMY be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for HRMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRMY
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
HRMY or TECH: Which Is the Better Value Stock Right Now?
HRMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
HRMY vs. TECH: Which Stock Is the Better Value Option?
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q4 Earnings and Revenue Estimates
HRMY or ILMN: Which Is the Better Value Stock Right Now?
Other News for HRMY
HARMONY BIOSCIENCES TO PARTICIPATE IN GOLDMAN SACHS 45th ANNUAL GLOBAL HEALTHCARE CONFERENCE
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo
RSPH: Healthcare Dashboard For May 2024
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Commit To Purchase Harmony Biosciences Holdings At $17.50, Earn 13.4% Annualized Using Options